Blog
RSS FeedPosted by Michael Wonder on 06 Jan 2026
NICE recommends new treatment option for highly active multiple sclerosis
2 January 2026 - Thousands of people living with a form of multiple sclerosis will benefit from greater treatment choice, following ...
Posted by Michael Wonder on 24 Dec 2025
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
24 December 2025 - More than 7,000 people in England will now be able to access to a life-extending treatment for ...
Posted by Michael Wonder on 12 Dec 2025
Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses
1 December 2025 - Tens of thousands of NHS patients will benefit from a landmark trade deal between the UK and the ...
Posted by Michael Wonder on 03 Dec 2025
To avoid tariffs, UK agrees to Trump’s demand to pay more for drugs
3 December 2025 - President Trump has complained that wealthy countries like Britain pay too little for drugs, leading America to ...
Posted by Michael Wonder on 27 Nov 2025
MHRA approves inavolisib for the treatment of breast cancer
26 November 2025 - The MHRA has today approved inavolisib (Itovebi) for the treatment of adults with a type of breast ...
Posted by Michael Wonder on 26 Nov 2025
UK set to raise prices of drugs in US agreement
23 November 2025 - The UK Government is in the late stages of agreeing a major drug pricing deal with ...
Posted by Michael Wonder on 31 Oct 2025
NICE’s backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions
30 October 2025 - Today we’ve published final draft guidance recommending abiraterone and its generic variants in combination with androgen ...
Posted by Michael Wonder on 24 Oct 2025
Up to 6,000 patients to benefit from NICE-approved life-extending prostate cancer drug
24 October 2025 - People living with metastatic prostate cancer in England will gain access to a new treatment combination from ...
Posted by Michael Wonder on 22 Oct 2025
Sarilumab for the treatment of children/adolescents 2-17 years of age with polyarticular or oligoarticular juvenile idiopathic arthritis
22 October 2025 - NICE is unable to make a recommendation on the use of sarilumab (Kevzara) for the treatment of ...
Posted by Michael Wonder on 22 Oct 2025
Clascoterone for the treatment of patients 12 years of age and older with acne vulgaris
22 October 2025 - NICE is unable to make a recommendation on the use of clascoterone (Winlevi) for the treatment of patients ...
Posted by Michael Wonder on 17 Oct 2025
First HIV prevention injection for people unable to have daily PrEP recommended
17 October 2025 - A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small ...
Posted by Michael Wonder on 17 Oct 2025
Same time decisions on licensing and value - what pharmaceutical companies need to know
10 October 2025 - Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and ...
Posted by Michael Wonder on 11 Oct 2025
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
10 October 2025 - Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them ...
Posted by Michael Wonder on 09 Oct 2025
Why the Government must urgently raise the NICE cost effectiveness threshold
7 October 2025 - NICE plays an important role in determining whether new medicines will be funded for NHS patients ...
Posted by Michael Wonder on 08 Oct 2025
Britain prepares NHS drug spending hike to stave off Trump tariffs
8 October 2025 - The UK Government has drawn up proposals to increase the amount the National Health Service pays ...